Definitive Contract HHSD200201564147C
Award Date
9/29/15
Potential Completion Date
8/31/17
Potential Value
$1M
Federal Agency
CDC Pittsburgh
Awardee
Antagen Biosciences Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Boston, MA 02118, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This federal contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals. The $599,997.00 contract is a Firm Fixed Price Definitive Contract under the SBIR Program Phase I Action for the Major Program Code DAIDS. The purpose of the contract is to evaluate and modulate the molecular pathways involved in regulating and...
Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, has been awarded a $299,998 firm fixed price Small Business Innovation Research (SBIR) contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Antagen will further develop its novel protein nanoparticle-based expression and delivery system using FcRider technology and antibody afucosylation technology to produce an engineered HIV envelope glycoprotein...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 definitive contract to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, as part of the Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from July 5, 2022 through November 30, 2023 to be performed in Canton, Massachusetts. The award is set aside for...
This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization...
This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,961, was awarded to Molecular Express Inc. to identify a potential HIV antigen-conjugated vaccine formulation. The contractor will explore co-delivery of HIV antigens and adjuvant molecules, as requested in the NIH/CDC SBIR solicitation seeking proposals on alternatives to cell culture materials, various cancer-related technologies, opioid withdrawal...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...